Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0.0333333333333334 0.222222222222222 0.388888888888889
Stock impact report

Mateon to Develop its OT-101, a Phase 3 Clinical Drug Candidate, Initially Against COVID-19

MATEON THERAPEUTICS (MATN) 
Last mateon therapeutics earnings: 11/19 05:25 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.mateon.com
Company Research Source: GlobeNewswire
OT-101- a TGF-ß2 inhibitor - has demonstrated potent antiviral activity against coronavirus   OT-101 - an RNA therapeutic - is part of the Company’s proprietary platform for rapid antiviral response AGOURA HILLS, Calif., March 18, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) dedicated to development OT-101, a TGF-Beta antisense drug candidate, today provided an update on its rapid antiviral response program against coronaviruses, with a target of the coronavirus, initially the COVID-19 virus. Mateon has made significant progress in deploying its phase 3 clinical asset, OT-101, against coronavirus. In an in vitro antiviral testing performed by an independent laboratory, OT-101 has an 50% effective concentration (EC50) of 7.6 µg/mL and is not toxic at the highest dose of 1000 µg/mL giving a safety index (SI) value of 130, which is considered highly active. Mateon intends to work with the Food and Drug Administration (FDA) to permit OT-101 to en Show less Read more
Impact Snapshot
Event Time:
MATN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for MATN alerts
Opt-in for
MATN alerts

from News Quantified
Opt-in for
MATN alerts

from News Quantified